Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
3 June 2019 American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
17 December 2020 Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
3 June 2019 American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
17 December 2020 Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
3 June 2019 American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
17 December 2020 Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
